Lu et al. observed that sorafenib combined with 20(S)-Rg3 significantly reduced the viability of human HCC cell lines HepG2 and Huh7, promoted apoptosis, increased chemotherapy sensitivity, and reversed chemoresistance by modulating the PTEN/Akt signaling pathway. The gene discussed is AKT1; the disease is hepatocellular carcinoma.